Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Study shows medical professionals use supplements

This article was originally published in The Tan Sheet

Executive Summary

A peer-reviewed study in the July 1 Nutrition Journal finds 72 percent of physicians and 89 percent of nurses use supplements, and 79 percent of physicians and 82 percent of nurses recommend them to patients. The study, which showed multivitamins were most commonly used, examined data from the Council for Responsible Nutrition's "Life...supplemented" Healthcare Professionals Impact Study (1"The Tan Sheet" Nov. 19, 2007). The authors -- CRN executive Andrew Shao, CRN past president Annette Dickinson and Ipsos Public Affairs Senior VP Nicolas Boyon -- say it may be "surprising that physicians and nurses are as likely as the general population" to use supplements "given the negative views sometimes expressed editorially in medical journals.

You may also be interested in...



Most Health Care Providers Use And Recommend Supplements – CRN Study

Results of a Council for Responsible Nutrition survey show not only are a majority of health-care providers using dietary supplements, even those who do not use them are recommending the products to patients

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel